Dark Adaptation as an Early Indicator of Response to Statin Therapy for Intermediate AMD

NCT04735263 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

21

Enrollment

OTHER

Sponsor class

Conditions

Age-related Macular Degeneration

Interventions

DRUG: Atorvastatin 80mg

Sponsor

Massachusetts Eye and Ear Infirmary